NGM trial fail. A commercial decision???This 25 min discussion is well worth listening to.
The suggestion is the trial didn't really fail clinically but NGM made a commercial decision because the company couldn't see a position for the drug in the market. Seems like a pretty brave decision for the company to make to pull the plug at that point. It's worth listening to the end, it sounds compelling to me.
https://surfingnash.com/s2-e28-special-episode-what-can-we-learn-the-aldafermin-discontinuation-in-f2-f3-nash/ So it shows what a negative impact this fail was for the whole NASH sector in terms of the reporting but if you accept this argument then clearly it shouldn't have been.